Samsung Biologics debuts dual antibody platform S-DUAL
이 글자크기로 변경됩니다.
(예시) 가장 빠른 뉴스가 있고 다양한 정보, 쌍방향 소통이 숨쉬는 다음뉴스를 만나보세요. 다음뉴스는 국내외 주요이슈와 실시간 속보, 문화생활 및 다양한 분야의 뉴스를 입체적으로 전달하고 있습니다.
The company said on Thursday it recently completed a patent application for the platform technology, which will facilitate applications to the development and production of various next-generation multi-antibody and other therapeutics in the future.
S-DUAL, a technology that combines two antibodies together, is known to outdo existing dual antibodies in terms of safety and production efficiency. Samsung Biologics expects that S-DUAL will greatly enhance its service lineup across the contract development and manufacturing business.
[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]
Copyright © 매일경제 & mk.co.kr. 무단 전재, 재배포 및 AI학습 이용 금지
- Korean prosecution arrests culprits behind $700 mn illegal overseas remittances - Pulse by Maeil Business News Korea
- Five Guys to open its first S. Korean restaurant with Hanwha in 2023 - Pulse by Maeil Business News Korea
- Korean Air, Airbus to jointly develop surveillance drone for Korean navy - Pulse by Maeil Business News Korea
- POSCO-GS joins hands to make inroad into battery recycling business - Pulse by Maeil Business News Korea
- S. Korea to consider tax benefits to venture capital investments - Pulse by Maeil Business News Korea
- 강경준, 상간남 피소…사랑꾼 이미지 타격 [MK픽] - 스타투데이
- ‘큰집’만 예외?…SK바사 M&A에 ‘수군수군’ [재계 TALK TALK]
- ‘결혼 4주년’ 맞은 우혜림, 임신 14주차 땡콩이 엄마! “오늘은 둘만 데이트” - MK스포츠
- 이찬원, 이태원 참사에 "노래 못해요" 했다가 봉변 당했다 - 스타투데이
- 양희은·양희경 자매, 오늘(4일) 모친상 - 스타투데이